Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 4/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15354396 | 0.82 | ALDH1A1 (0.53) | LMNATDP1SMN1; SMN2ALDH1A1CYP19A1 | |
| SCHEMBL11573009 | 0.81 | ALDH1A1 (0.59) | LMNATDP1SMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL27606133 | 0.81 | SMN1; SMN2 (0.52) | LMNASMN1; SMN2ALDH1A1MEN1NPC1 | |
| SCHEMBL14021916 | 0.81 | ALDH1A1 (0.55) | LMNATDP1SMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL27258849 | 0.80 | SMN1; SMN2 (0.50) | LMNATDP1SMN1; SMN2ALDH1A1CYP19A1 | |
| SCHEMBL12301170 | 0.80 | CHRNB2 (0.57) | TDP1NOTUMCHRNB2CHRNA4KDM4E | |
| SCHEMBL30163333 | 0.79 | LMNA (0.60) | LMNATDP1SMN1; SMN2ALDH1A1CYP19A1 | |
| SCHEMBL14022002 | 0.79 | SMN1; SMN2 (0.53) | LMNATDP1SMN1; SMN2ALDH1A1CYP19A1 | |
| SCHEMBL15015154 | 0.79 | MAPK14 (0.55) | LMNASMN1; SMN2ALDH1A1MEN1NPC1 | |
| SCHEMBL1446495 | 0.78 | SMN1; SMN2 (0.49) | LMNATDP1SMN1; SMN2ALDH1A1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210130473-A1 | TGFßR1 INHIBITOR-ASGR ANTIBODY CONJUGATES AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. | 2021-05-06 | — | — | US | disclosed |
| EP-3808740-A1 | ORAL DOSAGE FORMS COMPRISING 4-PHENYL-6-(2,2,2-TRIFLUORO-1-PHENYLETHOXY)PYRIMIDINE-BASED COMPOUNDS AND METHODS OF THEIR USE | TerSera Therapeutics LLC (US) | 2021-04-21 | — | — | EP | disclosed |
| WO-2021011834-A1 | ALK5 INHIBITORS, CONJUGATES, AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. (US) | 2021-01-21 | — | — | WO | disclosed |
| EP-3176159-B1 | 4-PHENYL-6-(2,2,2-TRIFLUORO-1-PHENYLETHOXY)PYRIMIDINE-BASED COMPOUNDS AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS INC (US) | 2020-10-21 | — | — | EP | disclosed |
| EP-2091940-B3 | 4-PHENYL-6-(2,2,2-TRIFLUORO-1-PHENYLETHOXY)PYRIMIDINE-BASED COMPOUNDS AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS INC (US) | 2017-12-06 | — | — | EP | disclosed |
| EP-3176159-A1 | 4-PHENYL-6-(2,2,2-TRIFLUORO-1-PHENYLETHOXY)PYRIMIDINE-BASED COMPOUNDS AND METHODS OF THEIR USE | Lexicon Pharmaceuticals, Inc. (US) | 2017-06-07 | — | — | EP | disclosed |
| EP-3144303-A1 | 6-SUBSTITUTED PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES | Array Biopharma, Inc. (US) | 2017-03-22 | — | — | EP | disclosed |
| EP-2589600-B1 | 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use | LEXICON PHARMACEUTICALS INC (US) | 2017-02-15 | — | — | EP | disclosed |
| US-9556139-B2 | 6-substituted phenoxychroman carboxylic acid derivatives | ARRAY BIOPHARMA INC. (US) | 2017-01-31 | — | — | US | disclosed |
| US-20150232442-A1 | 6-SUBSTITUTED PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES | ARRAY BIOPHARMA INC. (US) | 2015-08-20 | — | — | US | disclosed |
| US-8772482-B2 | 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-8716498-B2 | 6-substituted phenoxychroman carboxylic acid derivatives | ARRAY BIOPHARMA, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-8569522-B2 | 6-substituted phenoxychroman carboxylic acid derivatives | ARRAY BIOPHARMA INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-20130137635-A1 | TRYPTOPHAN HYDROXYLASE INHIBITORS FOR THE TREATMENT OF METASTATIC BONE DISEASE | LEXICON PHARMACEUTICALS, INC. (US) | 2013-05-30 | — | — | US | disclosed |
| EP-2589600-A1 | 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use | Lexicon Pharmaceuticals, Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| US-20120149691-A1 | Pyrrolo [1,2-b] Pyridazine Derivatives as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-8178490-B2 | Polybasic bacterial efflux pump inhibitors and therapeutic uses thereof | REMPEX PHARMACEUTICALS, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20120041008-A1 | 4-Phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-Based Compounds and Methods of Their Use | TERSERA THERAPEUTICS LLC | 2012-02-16 | — | — | US | disclosed |
| US-20100152098-A1 | POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | MPEX PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149691-A1 | Pyrrolo [1,2-b] Pyridazine Derivatives as Janus Kinase Inhibitors | JAK1, JAK2, JAK3 | LMNA 4792/4885TDP1 1716/4885SMN1; SMN2 3917/4885 |
| US-20100152098-A1 | POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | ABCB11, ABCB1, SLC47A1 | LMNA 3488/4885TDP1 2111/4885SMN1; SMN2 4857/4885 |
| US-20120041008-A1 | 4-Phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-Based Compounds and Methods of Their Use | TPMT, DPYD, TYMP | LMNA 1478/4885TDP1 153/4885SMN1; SMN2 654/4885 |
| US-20150232442-A1 | 6-SUBSTITUTED PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES | GPR52, CD22, CD74 | LMNA 3072/4885TDP1 3500/4885SMN1; SMN2 2925/4885 |
| US-20130137635-A1 | TRYPTOPHAN HYDROXYLASE INHIBITORS FOR THE TREATMENT OF METASTATIC BONE DISEASE | TPH1, TPH2, IDO1 | LMNA 3504/4885TDP1 1062/4885SMN1; SMN2 3954/4885 |
| US-20210130473-A1 | TGFßR1 INHIBITOR-ASGR ANTIBODY CONJUGATES AND USES THEREOF | TGFBR2, ASGR1, TGFBR1 | LMNA 2736/4885TDP1 4255/4885SMN1; SMN2 3891/4885 |
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | JAK2, JAK1, JAK3 | LMNA 4638/4885TDP1 2833/4885SMN1; SMN2 4199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.